(3S,4S,5R,6R)-2-bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S,4S,5R,6R)-2-bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)
• 英文别名: [(2R,3R,4S,5S)-6-bromo-3,4,5-tris(2,2-dimethylpropanoyloxy)oxan-2-yl]methyl 2,2-dimethylpropanoate
• 化学式: C₂₆H₄₃BrO₉
• 分子量: 579.526
• InChiKey: BSDBCYHGMPHOAL-LPNAZMDGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  36
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  114
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (3S,4S,5R,6R)-2-bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate) 、 烯丙醇 在 2,6-二甲基吡啶 作用下， 反应 20.0h， 以7 g的产率得到
  参考文献：
  名称：

  Polymerization of mannosyl tricyclic orthoesters for the synthesis of α(1–6) mannopyranan—the backbone of lipomannan

  摘要：

  Tuberculosis (TB) remains a major health problem worldwide. Understanding the interactions between the surface components of Mycobacterium tuberculosis (Mtb), the main causative agent of TB, with host immune response will be critical for developments of effective treatments and prevention of TB. Chemically defined mimics of the bacterial envelope components serve as important tools for biological studies of the bacterial interactions with mammalian hosts. We report here a rapid synthetic approach utilizing mannosyl tricyclic orthoesters as monomers for regio- and stereo-controlled polymerizations to generate alpha(1-6) mannopyranan-the backbone of lipomannan. The polymerizations generated multiple glycosidic bonds in a single chemical transformation in regio- and stereo-selective manners. TMSOTf is the optimum catalyst to promote the selective and high yielding polymerization when compared with other Lewis acids. In addition, the monomers 3,4-O-benzyl-beta-D-mannopyranose 1,2,6-orthobenzoate (1) and 3,4-O-benzyl-beta-D-mannopyranose 1,2,6-orthopivalate (2) can be synthesized in multiple-gram scale and in a rapid fashion. Characterizations by GPC and NMR indicate the identity of alpha(1-6) mannopyranan with DPn (degree of polymerization) = 20. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.04.014
• 作为产物：
  描述：

  D-mannose pentapivaloate 在 氢溴酸 、 乙酸酐 、 溶剂黄146 作用下， 反应 24.0h， 生成 (3S,4S,5R,6R)-2-bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)
  参考文献：
  名称：

  Polymerization of mannosyl tricyclic orthoesters for the synthesis of α(1–6) mannopyranan—the backbone of lipomannan

  摘要：

  Tuberculosis (TB) remains a major health problem worldwide. Understanding the interactions between the surface components of Mycobacterium tuberculosis (Mtb), the main causative agent of TB, with host immune response will be critical for developments of effective treatments and prevention of TB. Chemically defined mimics of the bacterial envelope components serve as important tools for biological studies of the bacterial interactions with mammalian hosts. We report here a rapid synthetic approach utilizing mannosyl tricyclic orthoesters as monomers for regio- and stereo-controlled polymerizations to generate alpha(1-6) mannopyranan-the backbone of lipomannan. The polymerizations generated multiple glycosidic bonds in a single chemical transformation in regio- and stereo-selective manners. TMSOTf is the optimum catalyst to promote the selective and high yielding polymerization when compared with other Lewis acids. In addition, the monomers 3,4-O-benzyl-beta-D-mannopyranose 1,2,6-orthobenzoate (1) and 3,4-O-benzyl-beta-D-mannopyranose 1,2,6-orthopivalate (2) can be synthesized in multiple-gram scale and in a rapid fashion. Characterizations by GPC and NMR indicate the identity of alpha(1-6) mannopyranan with DPn (degree of polymerization) = 20. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.04.014

文献信息

• [EN] MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS DE MANNOSE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：VERTEX PHARMA

  公开号：WO2014100158A1

  公开（公告）日：2014-06-26

  The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula (I). The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

  本发明涉及用于治疗或预防细菌感染的化合物。这些化合物具有化学式（I）。该发明还提供含有这些化合物的药学上可接受的组合物，以及使用这些组合物治疗细菌感染的方法。最后，该发明提供了制备本发明化合物的方法。
• MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20140243283A1

  公开（公告）日：2014-08-28

  The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

  本发明涉及用于治疗或预防细菌感染的化合物。这些化合物的化学式为I：本发明还提供包含该化合物的药学上可接受的组合物，并提供使用该组合物治疗细菌感染的方法。最后，本发明提供了制备该化合物的方法。
• Mannose Derivatives for Treating Bacterial Infections
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20160235775A1

  公开（公告）日：2016-08-18

  The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

  本发明涉及用于治疗或预防细菌感染的化合物。这些化合物的化学式为I：本发明还提供了含有这些化合物的药学上可接受的组合物以及使用这些组合物治疗细菌感染的方法。最后，本发明还提供了制备本发明化合物的方法。
• Mannose derivatives for treating bacterial infections
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10669298B2

  公开（公告）日：2020-06-02

  The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

  本发明涉及可用于治疗或预防细菌感染的化合物。这些化合物具有式 I： 本发明还提供了含有这些化合物的药学上可接受的组合物，以及使用这些组合物治疗细菌感染的方法。最后，本发明提供了制造本发明化合物的工艺。
• 2,7-dibromospiro[fluorene-9,4′-piperidine] compounds
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10913761B2

  公开（公告）日：2021-02-09

  The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

  本发明涉及可用于治疗或预防细菌感染的化合物。这些化合物具有式 I： 本发明还提供了含有这些化合物的药学上可接受的组合物，以及使用这些组合物治疗细菌感染的方法。最后，本发明提供了制造本发明化合物的工艺。